Compare ARK Genomic Revolution ETF (ARKG) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nebius Group NV — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Nebius Group NV trades at $212.38 (market cap $55.77B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| ARKG | NBIS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $286.69 |
52-Week Low | $23.09 | $44.30 |
Market Cap | — | $55.77B |
Enterprise Value | — | $55.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
NBIS trades at $219.65, up 1.6% over the past day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $529.80 million in 2025 with a net income of $82.50 million, and analyst consensus is strongly bullish with an average price target of $248.00. Recent news highlights aggressive AI infrastructure expansion and partnerships, though volatility persists amid sector competition fears.
Outlook remains positive given strong analyst buy ratings and projected revenue growth to $878 million in 2026, but high valuation multiples and competitive threats from tech giants like Meta pose significant risks. Cash flow trends show heavy investing activity funded by financing, supporting growth but elevating leverage concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
